Clinical Trial

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

Study acronym: CVL009-C2001
Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 25, 2024 (before its estimated February 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06519110
Lead Sponsor Convalife (Shanghai) Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 60 participants
Start Date 2024-08-10
Primary Completion 2026-02-14 (estimated)
Study Completion 2026-04-15 (estimated)
Updated on ClinicalTrials.gov 2024-07-25